The p53 pathway is disrupted in virtually every human tumor. In∼ 50% of human cancers,
the p53 gene is mutated, and in the remaining cancers, the pathway is dysregulated by …

Cancer cells often have high expression of Mdm2. However, in many cancers mdm2 is
alternatively spliced, with more than 40 mRNA variants identified. Many of the alternative …

Many types of human cancers overexpress MDM2 protein. A common characteristic among
these cancers is an associated increase in mdm2 splice variants. Provided here is a …

The MYCN gene has a critical role in determining the clinical behavior of neuroblastoma.
Although it is known that genomic amplification occurs in high-risk subsets, it remains …

Human cancers over-expressing mdm2, through a T to G variation at a single nucleotide
polymorphism at position 309 (mdm2 SNP309), have functionally inactivated p53 that is not …

The murine double minute 2 (MDM2) protein is a major negative regulator of the tumour
suppressor protein p53. Under normal conditions, MDM2 constantly binds to p53 …

MDM2 is a 90 kDa nucleo-phosphoprotein that binds p53 and other proteins contributing to
its oncogenic properties. Its structure includes an amino proximal p53 binding site, a central …

Background: MYCN-amplification is a major negative prognostic marker, occurring in 25-
30% of neuroblastomas. MYCN plays contradictory roles in promoting cell growth and …